Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.

Clinical pharmacology and therapeutics - 1 Dec 2005

Mouly Stéphane J, Matheny Chris, Paine Mary F, Smith Glenn, Lamba Jatinder, Lamba Vishal, Pusek Susan N, Schuetz Erin G, Stewart Paul W, Watkins Paul B

Abstract excerpt

OBJECTIVE: Saquinavir, a widely prescribed human immunodeficiency virus 1 protease inhibitor, has a low and variable oral bioavailability that has been attributed to extensive first-pass extraction mediated by hepatic or intestinal cytochrome P450 (CYP) 3A4 and intestinal P-glycoprotein (P-gp). The polymorphic CYP3A5 has also been shown to influence the saquinavir metabolite/parent urinary ratio, suggesting a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Beverages
Share to Biological Availability

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carbon Radioisotopes

Share to Citrus

Share to Cross-Over Studies

Share to Enterocytes

Share to Metabolic Clearance Rate

Share to Saquinavir

Source

Identifiers

PMID: 16338276
DOI: 10.1016/j.clpt.2005.08.014

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.PMID 16338276Read ↗

CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir.Semantic proximity Read ↗

Lack of sex-related differences in saquinavir pharmacokinetics in an HIV-seronegative cohort.Semantic proximity Read ↗

Effects of the CYP3A5 genotype on omeprazole sulfoxidation in CYP2C19 PMs.Semantic proximity Read ↗

CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children.Semantic proximity Read ↗

Pharmacokinetic variability of clarithromycin and differences in CYP3A4 activity in patients with cystic fibrosis.Semantic proximity Read ↗

The effect of ABCB1 polymorphism on the pharmacokinetics of saquinavir alone and in combination with ritonavir.Semantic proximity Read ↗

Cytochrome P450 3A5 plays a prominent role in the oxidative metabolism of the anti-human immunodeficiency virus drug maraviroc.Semantic proximity Read ↗

Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: Lack of prediction by the erythromycin breath testSemantic proximity Read ↗

Oral contraception does not alter single dose saquinavir pharmacokinetics in women.Semantic proximity Read ↗

Effects of grapefruit juice on intestinal P-glycoprotein: evaluation using digoxin in humans.Semantic proximity Read ↗

Oral bioavailability of P-glycoprotein substrate drugs do not differ between ABCB1-1Δ and ABCB1 wild type dogs.Semantic proximity Read ↗

HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.